With fresh company building lessons from Ablynx, Edwin Moses is ready to try it again as chair of neoantigen biotech Achilles
After officially passing off Ablynx to Sanofi in July, Edwin Moses took August off — the longest break the biotech CEO has had in about 20 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
